Dietary fiber and gut microbiome modulation in chronic kidney disease progression: narrative mini-review
This narrative mini-review synthesizes plausible mechanisms by which dietary fiber may modulate the gut microbiome in CKD, but provides no clinical trial evidence to support a direct clinical benefit on renal function.
| Population | Patients with chronic kidney disease (stages 3–5, including transplant recipients and diabetic CKD patients) |
|---|---|
| Intervention | Dietary fiber intake (soluble and insoluble) and its effects on the gut microbiome |
| Comparator | Low-fiber diet or standard diet without fiber supplementation |
| Outcome | CKD progression (GFR); Uremic toxin production (TMAO, p-cresol sulfate); Gut microbial diversity; Short-chain fatty acid (SCFA) production; Inflammatory markers (CRP); Body weight and blood pressure control; Lipid profile and glycemic control |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| CKD progression (GFR) | not estimable; in the pooled data reported | — | Very low | — | |
| Uremic toxin production (TMAO, p-cresol sulfate) | directional only; in the pooled effect size or CI reported | — | Very low | — | |
| Gut microbial diversity | directional only; in the pooled effect size or CI reported | — | Very low | — | |
| Short-chain fatty acid (SCFA) production | directional only; in the pooled effect size or CI reported | — | Very low | — | |
| Inflammatory markers (CRP) | directional only; murine model; in the effect size or CI reported | — | Very low | — | 1 studies |
| Body weight and blood pressure control | directional only per KDIGO 2020 indirect evidence; in the pooled effect size or CI | — | Low | — | |
| Lipid profile and glycemic control | directional only; in the pooled effect size or CI reported | — | Low | — |
Context
CKD affects approximately 10% of the global population and generates excessive uremic toxin production driven by an altered gut microbiome. Modulation of the gut-kidney axis through dietary fiber is proposed as an adjuvant therapeutic target alongside standard care. The 2020 KDIGO Nutrition Guidelines already recommend adequate fiber intake from natural sources in CKD.
What the study showed
The review describes mechanisms by which fiber consumption increases short-chain fatty acid production (acetate, propionate, butyrate), reduces uremic toxins such as TMAO and p-cresol sulfate, and improves microbial diversity in experimental models and observational studies in CKD. Data from a murine CKD model on a high-fat diet showed reduced CRP after fiber intake, with no effect size quantified in the available full text. No randomized clinical trial with a primary renal function endpoint is cited as a central result. The 2020 KDIGO recommendation for fiber in CKD stages 3–5 is based on indirect evidence of reductions in body weight, blood pressure, and net acid production.
How it was done
Narrative mini-review, without a registered protocol, without a described systematic search, without explicit inclusion/exclusion criteria, and without formal risk-of-bias assessment of included studies. The review integrates data from animal models, observational studies, small clinical trials, and guidelines. No meta-analysis or quantitative synthesis was performed.
Effect magnitude
No pooled effect size with 95% CI is reported. Primary studies cited are heterogeneous in population, fiber type, dose, and outcome, preventing a reliable magnitude estimate.
Risk of bias
Narrative review without prospective registration (PROSPERO), without a systematic search strategy, and without risk-of-bias assessment (RoB 2 or AMSTAR-2 not applied). Study selection is potentially biased. Evidence quality is not differentiated by outcome (GRADE not applied). Most mechanistic data derive from preclinical or observational studies with small samples, limiting causal inference.
What this study does NOT prove
This study does not prove that dietary fiber supplementation slows CKD progression in humans, nor does it establish causality between microbiome modulation and preservation of renal function. Findings cannot be generalized to advanced CKD populations (stage 5/dialysis) or to patients with comorbidities not represented in the cited primary studies.
In clinical practice
Dietary fiber intake from natural sources (20–35 g/day) may be encouraged in CKD stages 3–5 patients, consistent with 2020 KDIGO recommendations, with attention to potassium and phosphorus balance from fruits and vegetables. Clinicians should not replace standard treatment with fiber intervention based on this review. Individualized monitoring of renal function and electrolytes remains mandatory.
Limitations
Narrative review without prospective registration (PROSPERO), without a systematic search strategy, and without risk-of-bias assessment (RoB 2 or AMSTAR-2 not applied). Study selection is potentially biased. Evidence quality is not differentiated by outcome (GRADE not applied). Most mechanistic data derive from preclinical or observational studies with small samples, limiting causal inference.
What is still missing
Randomized clinical trials with primary renal function endpoints (glomerular filtration rate) and hard composite renal outcomes, comparing specific fiber types and doses at different CKD stages, with at least 12 months of follow-up.
Technical appendix
Version history
- 1.0 · 2026-06-24 — Auto-generated under Evidence Standard v1.0